Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
nTapvN7NKb1J8reR
